Mandate

Vinge advises STMicroelectronics on its acquisition of a majority stake in Norstel AB

February 07, 2019 M&A

Vinge has advised the French-Italian electronics and semiconductor manufacturer STMicroelectronics in connection with STMicroelectronics entering into an agreement to acquire a majority stake in the Swedish silicon carbide wafer manufacturer Norstel AB.

Upon completion of the transaction (which is subject to conditions), STMicroelectronics will acquire 55% of Norstel AB, with an option to acquire the remaining 45% subject to certain conditions. If such option is exercised, it will result in a total consideration of USD 137,500,000 for 100% of Norstel AB.

Vinge’s team consisted of, among others, Christina Kokko, Ulrich Ziche, Linda Sengul and Desirée Sjöblom (Corporate and M&A), Gu Qun, Gabriella Fossum, Jasmin Draszka-Ali and Hayaat Ibrahim (Regulatory and Compliance), Klara Secher (IP), Sophia Holm and Lova Unge (Employment), Nicklas Thorgerzon (IT), Axel Jansson and Anna Åhlberg (Banking and Financing), Anne Wijkman (Real Estate/Lease Agreements), Trine Osen Bergkvist (Competition), Fredrika Hjelmberg (Commercial Agreements), Hampus Olsson (Environment) and Jessica Öijer (VDR assistant).
 

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026